Matteini Enrico, Diluvio Laura, Lambiase Sara, Cioni Arnaldo, Gaeta Shumak Ruslana, Costanza Gaetana, Lanna Caterina, Caldarola Giacomo, Bianchi Luca, Campione Elena
Dermatology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.
Clin Cosmet Investig Dermatol. 2024 Oct 5;17:2225-2230. doi: 10.2147/CCID.S461557. eCollection 2024.
Alopecia areata represents an autoimmune disease that specifically damages growing hair follicles on the scalp and/or around the body. Janus kinase inhibitors have been identified as an effective therapy in adult patients and topical formulations, such as Brevilin-A, might represent a well-tolerated treatment for mild-moderate disease in children and adolescents. The mechanism of action of Brevilin-A, a sesquiterpene lactone isolated from Centipeda minima, could consist in blocking STAT3 and STAT1 signaling as well as the JAKs activity by inhibiting the JAKs tyrosine kinase domain JH1. We report our cases of successful application of Brevilin-A in pediatric patients, suggesting this treatment as a safe and effective therapeutic option also for recalcitrant alopecia areata in pediatric population.
斑秃是一种自身免疫性疾病，会特异性地损害头皮和/或身体其他部位正在生长的毛囊。Janus激酶抑制剂已被确定为成人患者的有效治疗方法，而局部制剂，如Brevilin-A，可能是儿童和青少年轻度至中度疾病的耐受性良好的治疗方法。Brevilin-A是一种从最小石胡荽中分离出的倍半萜内酯，其作用机制可能包括通过抑制JAKs酪氨酸激酶结构域JH1来阻断STAT3和STAT1信号以及JAKs活性。我们报告了Brevilin-A在儿科患者中成功应用的病例，表明这种治疗方法对于儿科人群中难治性斑秃也是一种安全有效的治疗选择。
